New detalimogene bladder cancer data send the minnow’s stock up 47%.
ApexOnco Front Page
Recent articles
The response rate jumps to 30% with higher doses of IMA402.
Tamarack data are a 2024 catalyst, so why has MacroGenics brought forward a follow-on molecule?
New clinical trial entrants include the group’s attempt at targeting Sting, a field that has seen many setbacks.
BeiGene has a strong presence at this year’s AACR, which features several notable duels.
Projects from the likes of BioNTech, Transgene and Scancell will feature, but still have much to prove.
After beating Darzalex, GSK’s withdrawn anti-BCMA ADC beats Velcade in early multiple myeloma.
Of the big oncology deals since 2016, there are still plenty that could go either way.